Sk Kulkarni

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11915356/publications.pdf

Version: 2024-02-01

53 papers	2,954 citations	147566 31 h-index	168136 53 g-index
53 all docs	53 docs citations	53 times ranked	3440 citing authors

#	Article	IF	Citations
1	Synthesis and evaluation of variably substituted N-methyl tetrahydroisoquinolines and benzazepines as monoamine reuptake inhibitors. Results in Chemistry, 2022, 4, 100352.	0.9	1
2	Adenosinergic system: an assorted approach to therapeutics for drug addiction. Future Neurology, 2012, 7, 307-327.	0.9	3
3	Evaluation of Antidepressant-Like Activity of Novel Water-Soluble Curcumin Formulations and St. John's Wort in Behavioral Paradigms of Despair. Pharmacology, 2012, 89, 83-90.	0.9	33
4	Antidepressant-like effect of 1-(7-methoxy-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-YL)-cyclohexanol, a putative trace amine receptor ligand involves l-arginineâ€“nitric oxideâ€“cyclic guanosine monophosphate pathway. Neuroscience Letters, 2011, 503, 120-124.	1.0	7
5	Targeting oxidative stress, mitochondrial dysfunction and neuroinflammatory signaling by selective cyclooxygenase (COX)-2 inhibitors mitigates MPTP-induced neurotoxicity in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 974-981.	2.5	27
6	Nitric oxide and major depression. Nitric Oxide - Biology and Chemistry, 2011, 24, 125-131.	1.2	183
7	Evaluation of antidepressant activity of 1-(7-methoxy-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-YL)-cyclohexanol, a Î²-substituted phenylethylamine in mice. European Neuropsychopharmacology, 2011, 21, 705-714.	0.3	5
8	An overview of curcumin in neurological disorders. Indian Journal of Pharmaceutical Sciences, 2010, 72, 149.	1.0	108
9	Potentials of Curcumin as an Antidepressant. Scientific World Journal, The, 2009, 9, 1233-1241.	0.8	112
10	Protective effect of cyclooxygenase (COX)-inhibitors against drug-induced catatonia and MPTP-induced striatal lesions in rats. Pharmacology Biochemistry and Behavior, 2009, 94, 219-226.	1.3	23
11	Cyclooxygenase in epilepsy: from perception to application. Drugs of Today, 2009, 45, 135.	0.7	49
12	Estimation of adenosine and its major metabolites in brain tissues of rats using high-performance thin-layer chromatographyâ€“densitometry. Journal of Chromatography A, 2008, 1209, 230-237.	1.8	13
13	Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor increases pentylenetetrazol seizure threshold in mice: Possible involvement of adenosinergic mechanism. Epilepsy Research, 2008, 78, 60-70.	0.8	54
14	Possible involvement of sigmaâ€1 receptors in the antiâ€immobility action of bupropion, a dopamine reuptake inhibitor. Fundamental and Clinical Pharmacology, 2008, 22, 387-394.	1.0	30
15	Nitric oxide signaling pathway in the anti-convulsant effect of adenosine against pentylenetetrazol-induced seizure threshold in mice. European Journal of Pharmacology, 2008, 587, 129-134.	1.7	38
16	Venlafaxine reverses chronic fatigue-induced behavioral, biochemical and neurochemical alterations in mice. Pharmacology Biochemistry and Behavior, 2008, 89, 563-571.	1.3	33
17	Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: Possible involvement of alpha-2 adrenergic receptors. Neuroscience Letters, 2008, 445, 83-88.	1.0	34
18	Withania somnifera: An Indian ginseng. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1093-1105.	2.5	279

#	Article	IF	Citations
19	Tiagabine, a GABA uptake inhibitor, attenuates 3-nitropropionic acid-induced alterations in various behavioral and biochemical parameters in rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 835-843.	2.5	30
20	Antidepressant-like effect of 17Î²-estradiol: involvement of dopaminergic, serotonergic, and (or) sigma-1 receptor systems. Canadian Journal of Physiology and Pharmacology, 2008, 86, 726-735.	0.7	43
21	Involvement of sigma (Ïƒ1) receptors in modulating the anti-depressant effect of neurosteroids (dehydroepiandrosterone or pregnenolone) in mouse tail-suspension test. Journal of Psychopharmacology, 2008, 22, 691-696.	2.0	32
22	Ascorbic acid inhibits development of tolerance and dependence to opiates in mice: Possible glutamatergic or dopaminergic modulation. Indian Journal of Pharmaceutical Sciences, 2008, 70, 56.	1.0	4
23	Effect of Addition of Yohimbine (Alpha-2-Receptor Antagonist) to the Antidepressant Activity of Fluoxetine or Venlafaxine in the Mouse Forced Swim Test. Pharmacology, 2007, 80, 239-243.	0.9	48
24	Involvement of l-arginineâ€“nitric oxideâ€“cyclic guanosine monophosphate pathway in the antidepressant-like effect of venlafaxine in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 921-925.	2.5	91
25	Effect of various classes of antidepressants in behavioral paradigms of despair. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1248-1254.	2.5	96
26	Involvement of dopamine (DA)/serotonin (5-HT)/sigma (Ïƒ) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist. Brain Research Bulletin, 2007, 74, 58-65.	1.4	45
27	Involvement of sigma-1 receptor modulation in the antidepressant action of venlafaxine. Neuroscience Letters, 2007, 420, 204-208.	1.0	30
28	Effect of systemic administration of adenosine on brain adenosine levels in pentylenetetrazol-induced seizure threshold in mice. Neuroscience Letters, 2007, 425, 39-42.	1.0	15
29	Systemic administration of adenosine ameliorates pentylenetetrazol-induced chemical kindling and secondary behavioural and biochemical changes in mice. Fundamental and Clinical Pharmacology, 2007, 21, 583-594.	1.0	16
30	Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. European Journal of Pharmacology, 2007, 568, 177-185.	1.7	116
31	Antagonistic Activity of Ascorbic Acid (Vitamin C) on Dopaminergic Modulation: Apomorphine-Induced Stereotypic Behavior in Mice. Pharmacology, 2006, 77, 38-45.	0.9	11
32	Comparative Brain Cholinesterase-Inhibiting Activity of Glycyrrhiza glabra, Myristica fragrans, Ascorbic Acid, and Metrifonate in Mice. Journal of Medicinal Food, 2006, 9, 281-283.	0.8	69
33	Protective Effect of Quercetin on Alcohol Abstinence-Induced Anxiety and Convulsions. Journal of Medicinal Food, 2005, 8, 392-396.	0.8	34
34	Improvement of Mouse Memory by Myristica fragrans Seeds. Journal of Medicinal Food, 2004, 7, 157-161.	0.8	78
35	Memory-Strengthening Activity of Glycyrrhiza glabra in Exteroceptive and Interoceptive Behavioral Models. Journal of Medicinal Food, 2004, 7, 462-466.	0.8	46
36	Phosphodiesterase 5 enzyme and its inhibitors: Update on pharmacological and therapeutical aspects. Methods and Findings in Experimental and Clinical Pharmacology, 2004, 26, 789.	0.8	66

#	Article	IF	Citations
37	Protective effect of bupropion on morphine tolerance and dependence in mice. Methods and Findings in Experimental and Clinical Pharmacology, 2004, 26, 623.	0.8	10
38	Fluoxetine suppresses morphine tolerance and dependence: Modulation of NO-cGMP/DA/serotoninergic pathways. Methods and Findings in Experimental and Clinical Pharmacology, 2003, 25, 273.	0.8	33
39	On the antinociceptive effect of fluoxetine, a selective serotonin reuptake inhibitor. Brain Research, 2001, 915, 218-226.	1.1	112
40	Comparative studies on the memory- enhancing actions of captopril and losartan in mice using inhibitory shock avoidance paradigm. Neuropeptides, 2001, 35, 65-69.	0.9	55
41	Tardive dyskinesia: An update. Drugs of Today, 2001, 37, 97.	0.7	36
42	Sex and Estrous Cycle-Dependent Changes in Neurosteroid and Benzodiazepine Effects on Food Consumption and Plus-Maze Learning Behaviors in Rats. Pharmacology Biochemistry and Behavior, 1999, 62, 53-60.	1.3	89
43	Brain renin angiotensin system (RAS) in stress-induced analgesia and impaired retention. Peptides, 1999, 20, 335-342.	1.2	57
44	The effects of neurosteroids on acquisition and retention of a modified passive-avoidance learning task in mice. Brain Research, 1998, 791, 108-116.	1.1	84
45	Modulation of motor functions involving the dopaminergic system by AT1 receptor antagonist, losartan. Neuropeptides, 1998, 32, 275-280.	0.9	18
46	Involvement of cholinergic system in losartan-induced facilitation of spatial and short-term working memory. Neuropeptides, 1998, 32, 417-421.	0.9	42
47	Differential anxiolytic effects of neurosteroids in the mirrored chamber behavior test in mice. Brain Research, 1997, 752, 61-71.	1.1	158
48	Role of D1/D2 dopamine and N-methyl-d-aspartate (NMDA) receptors in morphine tolerance and dependence in mice. European Neuropsychopharmacology, 1995, 5, 81-87.	0.3	25
49	GABA-mediated modification of despair behavior in mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 1989, 339, 306-11.	1.4	11
50	Molecular interactions of ethanol with GABAergic system and potential of RO15â€“4513 as an ethanol antagonist. Pharmacology Biochemistry and Behavior, 1988, 30, 501-510.	1.3	133
51	Reversal by alpha-2 agonists of diazepam withdrawal hyperactivity in rats. Psychopharmacology, 1986, 90, 198-202.	1.5	34
52	Modification of drug-induced catatonia and tremors by quipazine in rats and mice.. The Japanese Journal of Pharmacology, 1980, 30, 129-135.	1.2	18
53	Heat and other physiological stress-induced analgesia: Catecholamine mediated and naloxone reversible response. Life Sciences, 1980, 27, 185-188.	2.0	137